The scientific discipline of Immunology has always had an outstanding reputation in Denver. Approximately 50 faculty level immunologists provide a wide diversity of immunologic expertise in T and B cell biology and development, host defense, inflammation, apoptosis, autoimmunity, and structural biology related to immune function and dysfunction. Research by immunologists in Denver, including both UCCC members as well as non-members, has included many discoveries of high cancer relevance. The overall goal of the UCCC Program in Immunology/Imrnunotherapy is to describe how the basic elements of immunity affect cancer processes, and how cancer cells can evade the immune system. This understanding will provide avenues to develop new intervention strategies to reduce the cancer burden, both through prevention and treatment. The program has 43 full and 8 associate members holding primary appointments in the Departments of Cell and Structural Biology, Dermatology, Immunology, Medicine, Neurology, Pathology, Pediatrics, Radiology, Radiation Oncology and Surgery. The group includes several high-ranking scientists, including Chairs of the Departments of Immunology, Dermatology and Neurology, three members of the National Academy of Sciences, the Head of the Basic Immunology Division at National Jewish, the Directors of the Denver VA Flow Cytometry Core and the UCCC Immunology Core Laboratory, the Neuro-Oncology Clinical Trials Disease Chairman, the Director of Cancer Immunology of the Donal Monk Cancer Research Foundation, and the Head of the Denver National Jewish Medical and Research Center Division of Pediatric Allergy-Immunology. The Program members have over 17 million dollars in annual direct cost funding (-2.4 million from NCI) and of the 17 new Full Members recruited to the '17f program, six have received NCI funding. The future plan is to build on the successes in translating basic immunology into clinical interventions designed to prevent and treat cancer. This will be achieved by continuing strategic recruitments of immunologists with cancer translation interests, and by continuing to encourage the outstanding basic immunologists in Denver to focus their research interest in cancer and immunity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-25S2
Application #
8710563
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
25
Fiscal Year
2013
Total Cost
$963
Indirect Cost
$340
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62
Gillen, Austin E; Yamamoto, Tomomi M; Kline, Enos et al. (2016) Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics 17:338
Justice, Cristina M; Bishop, Kevin; Carrington, Blake et al. (2016) Evaluation of IRX Genes and Conserved Noncoding Elements in a Region on 5p13.3 Linked to Families with Familial Idiopathic Scoliosis and Kyphosis. G3 (Bethesda) 6:1707-12
Eckwahl, Matthew J; Arnion, Helene; Kharytonchyk, Siarhei et al. (2016) Analysis of the human immunodeficiency virus-1 RNA packageome. RNA 22:1228-38
Iguchi, Nao; Malykhina, Anna P; Wilcox, Duncan T (2016) Inhibition of HIF Reduces Bladder Hypertrophy and Improves Bladder Function in Murine Model of Partial Bladder Outlet Obstruction. J Urol 195:1250-6
Seedorf, Gregory; Metoxen, Alexander J; Rock, Robert et al. (2016) Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor-dependent preservation of growth in the developing lung. Am J Physiol Lung Cell Mol Physiol 310:L1098-110
Agarwal, Neeraj; Dancik, Garrett M; Goodspeed, Andrew et al. (2016) GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. Cancer Res 76:5175-85
Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322
Munson, Daniel J; Egelston, Colt A; Chiotti, Kami E et al. (2016) Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A 113:8272-7
Scott, Aaron J; Lieu, Christopher H; Messersmith, Wells A (2016) Therapeutic Approaches to RAS Mutation. Cancer J 22:165-74

Showing the most recent 10 out of 1302 publications